Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz raised the price target on Summit Therapeutics (NASDAQ: SMMT) to $43 from $40, while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
